Literature DB >> 35652296

Maternal High-Dose DHA Supplementation and Neurodevelopment at 18-22 Months of Preterm Children.

Mireille Guillot1, Anne Synnes2, Etienne Pronovost1, Mosarrat Qureshi3, Thierry Daboval4, Georges Caouette1, François Olivier5, Julie Bartholomew6, Ibrahim Mohamed7, Edith Massé8, Jehier Afifi9, Leonora Hendson10, Brigitte Lemyre4, Thuy Mai Luu7, Lannae Strueby11, Zenon Cieslak12, Kamran Yusuf10, Gustavo Pelligra13, Thierry Ducruet14, Aissatou Bintou Khairy Thilor Ndiaye1, Georgina Angoa1, Thibaut Sériès15, Bruno Piedboeuf1, Anne Monique Nuyt7, William Fraser16, Benoît Mâsse14,17, Thierry Lacaze-Masmonteil10, Pascal M Lavoie2, Isabelle Marc1.   

Abstract

OBJECTIVES: To determine whether maternal supplementation with high-dose docosahexaenoic acid (DHA) in breastfed, very preterm neonates improves neurodevelopmental outcomes at 18 to 22 months' corrected age (CA).
METHODS: Planned follow-up of a randomized, double-blind, placebo-controlled, multicenter trial to compare neurodevelopmental outcomes in breastfed, preterm neonates born before 29 weeks' gestational age (GA). Lactating mothers were randomized to receive either DHA-rich algae oil or a placebo within 72 hours of delivery until 36 weeks' postmenstrual age. Neurodevelopmental outcomes were assessed with the Bayley Scales of Infant and Toddler Development third edition (Bayley-III) at 18 to 22 months' CA. Planned subgroup analyses were conducted for GA (<27 vs ≥27 weeks' gestation) and sex.
RESULTS: Among the 528 children enrolled, 457 (86.6%) had outcomes available at 18 to 22 months' CA (DHA, N = 234, placebo, N = 223). The mean differences in Bayley-III between children in the DHA and placebo groups were -0.07 (95% confidence interval [CI] -3.23 to 3.10, P = .97) for cognitive score, 2.36 (95% CI -1.14 to 5.87, P = .19) for language score, and 1.10 (95% CI -2.01 to 4.20, P = .49) for motor score. The association between treatment and the Bayley-III language score was modified by GA at birth (interaction P = .07). Neonates born <27 weeks' gestation exposed to DHA performed better on the Bayley-III language score, compared with the placebo group (mean difference 5.06, 95% CI 0.08-10.03, P = .05). There was no interaction between treatment group and sex.
CONCLUSIONS: Maternal DHA supplementation did not improve neurodevelopmental outcomes at 18 to 22 months' CA in breastfed, preterm neonates, but subgroup analyses suggested a potential benefit for language in preterm neonates born before 27 weeks' GA.
Copyright © 2022 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35652296     DOI: 10.1542/peds.2021-055819

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   9.703


  2 in total

1.  Effects of maternal docosahexaenoic acid supplementation on brain development and neurodevelopmental outcomes of breastfed preterm neonates: protocol for a follow-up at preschool age of a randomised clinical trial (MOBYDIckPS).

Authors:  Mireille Guillot; Carole-Anne Robitaille; Laurence Turner; Etienne Pronovost; Georges Caouette; Célia Matte-Gagné; François Olivier; Julie Bartholomew; Édith Massé; Alyssa Morin; Ibrahim Mohamed; Isabelle Marc
Journal:  BMJ Open       Date:  2022-05-04       Impact factor: 3.006

2.  SMOFlipid Impact on Growth and Neonatal Morbidities in Very Preterm Infants.

Authors:  Suzan S Asfour; Belal Alshaikh; Latifah AlMahmoud; Haider H Sumaily; Nabeel A Alodhaidan; Mousa Alkhourmi; Hissah A Abahussain; Thanaa M Khalil; Bushra A Albeshri; Aroub A Alhamidi; Maha R Al-Anazi; Raneem S Asfour; Mountasser M Al-Mouqdad
Journal:  Nutrients       Date:  2022-09-23       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.